CN104936618A - 针对活化蛋白c的人源化单克隆抗体及其用途 - Google Patents

针对活化蛋白c的人源化单克隆抗体及其用途 Download PDF

Info

Publication number
CN104936618A
CN104936618A CN201380071700.3A CN201380071700A CN104936618A CN 104936618 A CN104936618 A CN 104936618A CN 201380071700 A CN201380071700 A CN 201380071700A CN 104936618 A CN104936618 A CN 104936618A
Authority
CN
China
Prior art keywords
antibody
ser
seq
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380071700.3A
Other languages
English (en)
Chinese (zh)
Inventor
X-Y.赵
Z.王
J-Y.金
Y.朱
J.特贝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CN104936618A publication Critical patent/CN104936618A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96461—Protein C (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380071700.3A 2012-11-29 2013-11-27 针对活化蛋白c的人源化单克隆抗体及其用途 Pending CN104936618A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261731368P 2012-11-29 2012-11-29
US61/731368 2012-11-29
PCT/US2013/072137 WO2014085527A1 (en) 2012-11-29 2013-11-27 Humanized monoclonal antibodies against activated protein c and uses thereof

Publications (1)

Publication Number Publication Date
CN104936618A true CN104936618A (zh) 2015-09-23

Family

ID=50828440

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380071700.3A Pending CN104936618A (zh) 2012-11-29 2013-11-27 针对活化蛋白c的人源化单克隆抗体及其用途

Country Status (17)

Country Link
US (2) USRE49099E1 (enExample)
EP (1) EP2925360A4 (enExample)
JP (1) JP2016501875A (enExample)
KR (1) KR20150088853A (enExample)
CN (1) CN104936618A (enExample)
AR (1) AR093672A1 (enExample)
AU (1) AU2013352260A1 (enExample)
BR (1) BR112015012458A2 (enExample)
CA (1) CA2892748A1 (enExample)
HK (1) HK1215174A1 (enExample)
IL (1) IL238920A0 (enExample)
MX (1) MX2015006738A (enExample)
RU (1) RU2015125343A (enExample)
SG (1) SG11201504035PA (enExample)
TW (1) TW201437229A (enExample)
UY (1) UY35160A (enExample)
WO (1) WO2014085527A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115611986A (zh) * 2021-07-13 2023-01-17 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) * 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
WO2020051277A1 (en) 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
KR20240152428A (ko) * 2022-03-04 2024-10-21 주식회사 코애귤런트테라퓨틱스 활성화된 단백질 c에 대한 인간 항체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121022A1 (en) * 2002-07-22 2006-06-08 Takaki Koga Apc non-neutralizing anti-body
CN101918453A (zh) * 2007-10-26 2010-12-15 俄克拉荷马医学研究基金会 针对活化蛋白c的单克隆抗体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US7247453B1 (en) 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5279956A (en) 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
PT1754718E (pt) 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
DE60141844D1 (de) 2000-10-02 2010-05-27 Oklahoma Med Res Found Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
US20030203355A1 (en) 2002-04-24 2003-10-30 Los Alamos National Laboratory Fluorobodies: binding ligands with intrinsic fluorescence
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US7662387B2 (en) 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
JP4829609B2 (ja) 2004-12-22 2011-12-07 独立行政法人科学技術振興機構 ヒト抗体酵素およびその生産方法
PL1963368T6 (pl) * 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
SI3219328T1 (sl) * 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
NZ574804A (en) 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a
US8039597B2 (en) 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
US20100291106A1 (en) 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060121022A1 (en) * 2002-07-22 2006-06-08 Takaki Koga Apc non-neutralizing anti-body
CN101918453A (zh) * 2007-10-26 2010-12-15 俄克拉荷马医学研究基金会 针对活化蛋白c的单克隆抗体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115611986A (zh) * 2021-07-13 2023-01-17 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
WO2023284012A1 (zh) * 2021-07-13 2023-01-19 美国俄克拉荷马医学研究基金会 针对人活化蛋白c的单克隆抗体及其制备和应用
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用

Also Published As

Publication number Publication date
EP2925360A1 (en) 2015-10-07
US20150322164A1 (en) 2015-11-12
KR20150088853A (ko) 2015-08-03
RU2015125343A (ru) 2017-01-11
WO2014085527A1 (en) 2014-06-05
US9657111B2 (en) 2017-05-23
CA2892748A1 (en) 2014-06-05
EP2925360A4 (en) 2016-07-13
AR093672A1 (es) 2015-06-17
MX2015006738A (es) 2015-08-05
JP2016501875A (ja) 2016-01-21
HK1215174A1 (zh) 2016-08-19
TW201437229A (zh) 2014-10-01
SG11201504035PA (en) 2015-06-29
IL238920A0 (en) 2015-07-30
AU2013352260A1 (en) 2015-06-11
UY35160A (es) 2014-06-30
BR112015012458A2 (pt) 2018-02-06
USRE49099E1 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
JP5801194B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6152090B2 (ja) 視神経脊髄炎を処置するための組成物および方法
US12084510B2 (en) Antibodies selective for cells presenting EGFR at high density
ES2356896T3 (es) Anticuerpos humanizados contra icam-1, su producción y usos.
TWI592426B (zh) 胞漿素原活化素抑制劑－１（ｐａｉ－１）之抗體及其用途
CN106163556A (zh) 基质金属蛋白酶底物和其它可切割部分及其使用方法
CN112142845A (zh) 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
CN113583116A (zh) 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途
USRE49099E1 (en) Humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
WO2015179435A1 (en) Optimized humanized monoclonal antibodies against activated protein c and uses thereof
TWI857319B (zh) 針對人活化蛋白c的單株抗體及其製備和應用
CN113880949A (zh) 凝血因子xi(fxi)结合蛋白
CN113880951A (zh) 凝血因子xi(fxi)结合蛋白
RU2824515C1 (ru) Моноклональное антитело к активированному белку с человека и его получение и применение
CN114080396A (zh) 抗-angpt2抗体
CN113880950A (zh) 凝血因子xi(fxi)结合蛋白
TW201609809A (zh) 活化蛋白ｃ之最佳化人化單株抗體及其用途
TW201609808A (zh) 抗活化蛋白ｃ之人類化單株抗體之抗原決定區基因定位及其用途
HK40081269A (en) Monoclonal antibody against human activated protein c and preparation and use thereof
TW202241964A (zh) 因子xia抑制劑之抗體及抗原結合肽及其用途
JP6419664B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
HK40052551B (en) Anti-fxi/fxia antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1215174

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150923

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1215174

Country of ref document: HK